This site contains information about prescription peptide therapy protocols intended for adults. You must be 18 years of age or older to enter.
By entering, you confirm you are at least 18 years old and agree to our Terms of Service. All protocols require a valid physician prescription.
The most potent growth hormone releasing peptide studied in humans — hexarelin produces the highest GH pulse amplitude of any GHRP via GHS-R1a agonism, without the appetite stimulation of GHRP-6 or the blunted output of GHRP-2. A second, distinct binding site on the CD36 receptor confers cardioprotective and anti-fibrotic effects independent of GH release — making hexarelin the only GHRP with a documented cardiac research application.
GHRPs (growth hormone releasing peptides) are a class of synthetic peptides that mimic ghrelin's action on the GHS-R1a (ghrelin receptor) in the pituitary and hypothalamus. Activating GHS-R1a triggers pituitary somatotrophs to release a burst of growth hormone — a pulse that mimics the body's natural pulsatile GH secretion pattern. Hexarelin was one of the first and most thoroughly studied synthetic GHRPs, and it remains the benchmark for raw GH secretagogue potency.
Compared to GHRP-6 and GHRP-2, hexarelin produces stronger GH release — but without the ghrelin-mediated appetite stimulation that makes GHRP-6 problematic for most researchers. GHRP-6 causes significant hunger and potential cortisol elevation via GHS-R1a; hexarelin's receptor binding profile at GHS-R1a differs subtly in a way that drives GH release without the same hunger signaling. The practical result: maximum GH output without eating everything in sight.
The second mechanism is the reason hexarelin occupies a unique place among GHRPs: it binds the CD36 receptor on cardiac muscle and endothelial cells. This binding — independent of GH release — has been linked to cardioprotective effects including reduced cardiac fibrosis, anti-apoptotic signaling in heart cells, and improved cardiac function in post-ischemic models. No other commercially available GHRP has this dual-receptor profile.
Hexarelin's high GHS-R1a affinity produces the strongest GH pulse — but also the fastest pituitary desensitization. Daily continuous use causes receptor downregulation and diminishing GH response within 4–8 weeks. This is why hexarelin research protocols often use intermittent schedules (5 days on, 2 days off, or 3 injections per day with extended off cycles) rather than uninterrupted daily dosing. Combining hexarelin with a GHRH analog (CJC-1295) produces synergistic GH release and may partially offset desensitization by maintaining somatotroph sensitization from the GHRH side.
Hexarelin produces the highest documented GH secretion peak of any GHRP in human studies. GH pulse amplitude determines downstream IGF-1 production, protein synthesis signaling, and fat mobilization — making peak output clinically relevant for GH-axis research.
GH elevation drives IGF-1 production in the liver, which mediates skeletal muscle protein synthesis, satellite cell activation, and recovery from exercise-induced damage. Hexarelin's high GH output makes it relevant for muscle preservation protocols, particularly in GH-deficient or aging populations.
Hexarelin's binding to CD36 on cardiac tissue is GH-independent. Research in cardiac ischemia models showed reduced cardiomyocyte apoptosis, decreased fibrosis, and improved left ventricular function after hexarelin treatment — effects that persisted when GH signaling was experimentally blocked, confirming the separate mechanism.
GH pulse amplitude correlates with lipolysis in adipose tissue. Higher GH peaks drive fat breakdown through hormone-sensitive lipase activation. Hexarelin's potency advantage translates to a meaningful body composition effect, particularly in visceral fat, when combined with appropriate nutrition and activity.
IGF-1 (driven by GH) is the primary anabolic signal for bone remodeling and density maintenance. In aging populations where GH pulsatility diminishes, GH secretagogues have been studied as a strategy to preserve bone density. Hexarelin's potent GH drive makes it relevant to this research angle.
The largest natural GH pulse occurs during slow-wave sleep. GHRP administration before bed amplifies this pulse — improving sleep-phase GH output and the tissue repair that depends on it. Bedtime dosing is one of the standard timing approaches in hexarelin research protocols.
Hexarelin produces the highest GH pulse amplitude of any GHRP tested in human studies — measurably stronger than GHRP-6, GHRP-2, and ipamorelin at equivalent molar doses.
The only GHRP with a documented non-GH receptor mechanism. CD36 binding on cardiac and endothelial tissue produces cardioprotective effects independent of the pituitary-GH axis — a research angle unique to hexarelin.
Human studies have used 1–2mcg/kg per injection. For a 70–80kg subject, this translates to 70–160mcg. The research community standard is 100–200mcg per injection, 2–3x daily.
Hexarelin is administered subcutaneously. Timing is critical: GH release from GHRPs is blunted significantly by elevated insulin or free fatty acids in the bloodstream. Injections should be given in a fasted state — away from meals, ideally 1.5–2 hours after eating or before breakfast. Somatostatin (the hormone that suppresses GH between pulses) is lowest in the early morning and late evening, making these windows most productive for GH secretagogue use.
| Protocol | Dose | Timing | Notes |
|---|---|---|---|
| Standard 2x daily | 100–200mcg SC | Morning fasted + bedtime | Two-injection protocol covering the morning low-somatostatin window and the sleep-phase GH pulse. Most common research schedule. |
| 3x daily | 100mcg SC | Morning / midday / bedtime | Three injections space GH pulses across the day. Midday must be fasted (1.5–2h from last meal, 30–45min before eating). Used in more intensive GH-axis research protocols. |
| Cardiac protocol | 100mcg SC | Once daily, fasted | For researchers focused specifically on CD36-mediated cardioprotection. Lower frequency reduces desensitization risk while maintaining consistent hexarelin exposure. |
| Cycle structure | — | — | 5 days on / 2 days off is the most common approach to manage GHS-R1a desensitization. Alternatively: 4–8 week on-cycle, 2–4 weeks off. Stack with CJC-1295 (GHRH) to maximize synergy and partially counteract desensitization. |
GHRH + GHRP combinations produce synergistic GH release — the GHRH primes the pituitary while the GHRP triggers the pulse. This is the gold standard GH secretagogue stack. CJC-1295 is the most commonly paired GHRH analog with hexarelin for this purpose.
5mg vials. The most potent GHRP in our catalog — Finnrick-verified purity, lot-specific COA, ships in 24 hours.
Begin Protocol Intake View All ProtocolsMedical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All protocols require evaluation and prescription by a licensed physician. You should consult a qualified healthcare provider before starting any new medical protocol. Individual results vary. Cinch Bio is not a pharmacy and does not dispense medications — all prescriptions are issued by independent licensed physicians and filled by licensed 503A compounding pharmacies.